Login to Your Account

Oxford BioMedica Buys Oxxon, In Share Offering Valued At £16M

By Nuala Moran

Wednesday, March 14, 2007

LONDON - Oxford BioMedica plc is acquiring its fellow immunotherapy specialist Oxxon Therapeutics Ltd. in an all-paper deal that values Oxxon at £12 million (US$23.3 million). In addition to six clinical stage products, the deal brings Oxford BioMedica £3 million in cash. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription